<DOC>
	<DOC>NCT01666691</DOC>
	<brief_summary>The purpose of this study is to evaluate weight reduction, safety and pharmacokinetics for certain doses of beloranib (ZGN-440 for injectable suspension) administered as twice-weekly subcutaneous injections for 12 weeks.</brief_summary>
	<brief_title>An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects</brief_title>
	<detailed_description>This protocol is designed to test the safety and efficacy of a drug called beloranib (ZGN-440 for injectable suspension). It is to be tested for its ability to reduce weight in obese subjects. The study will provide information on how much ZGN-440 gets into the blood, how long it stays in the body, and how it affects other biological markers.</detailed_description>
	<criteria>Obese volunteers weighing ≥ 50 kg BMI ≥ 30 and ≤ 50 kg/m2 Stable body weight during the past 2 months Type 2 diabetes mellitus is allowed Use of weight loss agents in the past month Current, clinically significant eating disorder Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Obese</keyword>
	<keyword>Obesity</keyword>
	<keyword>Overweight</keyword>
	<keyword>Weight loss</keyword>
	<keyword>Weight reduction</keyword>
	<keyword>Beloranib</keyword>
</DOC>